Vitamin D5
From Wikipedia, the free encyclopedia
![]() |
|
Names | |
---|---|
IUPAC name
(1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(1R,4S)-4-ethyl-1,5-dimethylhexyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylene-1-cyclohexanol
|
|
Identifiers | |
71761-06-3 ![]() |
|
3D model (Jmol) | Interactive image |
ChemSpider | 7826639 ![]() |
PubChem | 9547700 |
|
|
|
|
Properties | |
C29H48O | |
Molar mass | 412.69082 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
|
![]() ![]() ![]() |
|
Infobox references | |
Vitamin D5 is a form of vitamin D.
Analogues have been proposed for use as antitumor agents.[1][2][3]
See also[edit]
References[edit]
- ^ Mehta RG, Moriarty RM, Mehta RR, et al. (February 1997). "Prevention of preneoplastic mammary lesion development by a novel vitamin D analogue, 1alpha-hydroxyvitamin D5". J. Natl. Cancer Inst. 89 (3): 212–8. doi:10.1093/jnci/89.3.212. PMID 9017001.
- ^ Murillo G, Mehta RG (October 2005). "Chemoprevention of chemically-induced mammary and colon carcinogenesis by 1alpha-hydroxyvitamin D5". J. Steroid Biochem. Mol. Biol. 97 (1-2): 129–36. doi:10.1016/j.jsbmb.2005.06.008. PMID 16051482.
- ^ Mehta RG (October 2004). "Stage-specific inhibition of mammary carcinogenesis by 1alpha-hydroxyvitamin D5". Eur. J. Cancer. 40 (15): 2331–7. doi:10.1016/j.ejca.2004.05.025. PMID 15454260.
![]() |
This biochemistry article is a stub. You can help Wikipedia by expanding it. |